FREMONT, Calif.--(BUSINESS WIRE)--July 6, 2006--DiscoveRx Corporation today announced the launch of their PathHunter(TM) Beta-Arrestin assay, a universal G-protein coupled receptor (GPCR) screening platform that utilizes a proprietary ProLink(TM) tag along with the well established enzyme fragment complementation (EFC) technology. This launch further strengthens DiscoveRx leadership position as a provider of GPCR assays.
